Recombinant human thymosin beta4 - Beijing Northland Biotech

Drug Profile

Recombinant human thymosin beta4 - Beijing Northland Biotech

Alternative Names: NL-005; Recombinant human thymosin β4 - Beijing Northland Biotech

Latest Information Update: 20 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Beijing Northland Biotech
  • Developer Beijing Northland Biotech; Beijing Shijitan Hospital
  • Class Recombinant proteins
  • Mechanism of Action Actin modulators; Angiogenesis inducing agents; Apoptosis inhibitors; Collagen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Myocardial infarction

Most Recent Events

  • 18 Jul 2017 Phase-I clinical trials in Myocardial infarction (In volunteers) in China (unspecified route) (ChiCTR-IID17011983)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top